SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company […]
First quarter consolidated revenues were $3.8 billion on lower industry demand First quarter diluted EPS at $0.10 Results reflect continued execution […]